Global Chronic Lymphocytic Leukemia Therapeutics Market 2016-2020

2016-06-01
Price :
Published : Jun-2016
No. of Pages : 78

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:

  • Acute myeloid (or myelogenous) leukemia (AML)
  • Chronic myeloid (or myelogenous) leukemia (CML)
  • Acute lymphocytic (or lymphoblastic) leukemia (ALL)
  • CLL

The analysts forecast global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffman-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Gilead Sciences
  • Novartis
  • Johnson & Johnson

Other prominent vendors

  • Altor BioScience
  • Amgen
  • Arno Therapeutics
  • AstraZeneca
  • Bellicum Pharmaceuticals
  • Biogen
  • BioLineRx
  • Boston Biomedical
  • Celgene
  • Emergent BioSolutions
  • Genzyme
  • iDD biotech
  • Immunomedics
  • Infinity Pharmaceuticals
  • Innate Pharma
  • Karyopharm Therapeutics
  • Ligand Pharmaceuticals
  • MedImmune
  • Merck Sharp & Dohme
  • Molecular Templates Inc.
  • MorphoSys
  • Ono Pharmaceutical
  • Portola Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Sunesis Pharmaceuticals
  • TG Therapeutics
  • TheraMAB
  • XEME Biopharma
  • Xencor
  • ZIOPHARM Oncology

Market driver

  • Special regulatory designations
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Rise in development of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

ForeSights: Salt Therapy – An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution

ForeSights: Salt Therapy - An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution Summary Salt therapy is a non-invasive treatment that uses aerated salt or a salt bath to deliver health and wellness benefits. It comes in two forms: dry salt therapy (halotherapy) and wet salt therapy (flotation therapy). Both forms of salt therapy are claimed to promote relaxation and rejuvenation. Salt therapy is an old-fashioned, drug-free treatment leveraging the claimed natural antibacterial and anti-inflammatory properties of salt that capitalizes on growing interest in complementary and alternative medicine. Scope - Dry salt therapy (halotherapy) takes mineral-rich salt and grinds it into a fine powder that is dispensed into the air to cre......
$495

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2026 Summary Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining. To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative,......
$3995

Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2017

Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2017" provides an overview of Hematopoietic Stem Cell Transplantation clinical trials scenario. This report provides top line data relating to the clinical trials on Hematopoietic Stem Cell Transplantation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Repo......
$2500

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provide......
$1000

Hemiplegia Global Clinical Trials Review, H2, 2017

Hemiplegia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemiplegia Global Clinical Trials Review, H2, 2017" provides an overview of Hemiplegia clinical trials scenario. This report provides top line data relating to the clinical trials on Hemiplegia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500

Heart Transplant Rejection Global Clinical Trials Review, H2, 2017

Heart Transplant Rejection Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Heart Transplant Rejection Global Clinical Trials Review, H2, 2017" provides an overview of Heart Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary dat......
$2500

Heart Valve Disease Global Clinical Trials Review, H2, 2017

Heart Valve Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Heart Valve Disease Global Clinical Trials Review, H2, 2017" provides an overview of Heart Valve Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Valve Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017

Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017" provides an overview of Helicobacter pylori Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Helicobacter pylori Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's......
$2500

Helminthiasis Global Clinical Trials Review, H2, 2017

Helminthiasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helminthiasis Global Clinical Trials Review, H2, 2017" provides an overview of Helminthiasis clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Helminthic Infestations Global Clinical Trials Review, H2, 2017

Helminthic Infestations Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helminthic Infestations Global Clinical Trials Review, H2, 2017" provides an overview of Helminthic Infestations clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthic Infestations. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500